Free Trial

Brokerages Set Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Price Target at $60.00

Ionis Pharmaceuticals logo with Medical background
Remove Ads

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the twenty ratings firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $60.00.

Several equities analysts have recently commented on IONS shares. Needham & Company LLC reaffirmed a "buy" rating and set a $60.00 target price on shares of Ionis Pharmaceuticals in a report on Thursday, February 20th. Citigroup decreased their price target on Ionis Pharmaceuticals from $67.00 to $64.00 and set a "buy" rating for the company in a research note on Thursday, February 20th. Piper Sandler dropped their price objective on Ionis Pharmaceuticals from $65.00 to $62.00 and set an "overweight" rating on the stock in a research note on Thursday, November 14th. BMO Capital Markets cut their price objective on Ionis Pharmaceuticals from $60.00 to $45.00 and set a "market perform" rating for the company in a research report on Thursday, February 20th. Finally, StockNews.com lowered shares of Ionis Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Tuesday, November 12th.

View Our Latest Research Report on Ionis Pharmaceuticals

Remove Ads

Insiders Place Their Bets

In other news, EVP Patrick R. O'neil sold 6,165 shares of the stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $31.62, for a total value of $194,937.30. Following the transaction, the executive vice president now owns 57,452 shares of the company's stock, valued at $1,816,632.24. This represents a 9.69 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Brett P. Monia sold 38,843 shares of the company's stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $31.65, for a total value of $1,229,380.95. Following the completion of the sale, the chief executive officer now directly owns 180,683 shares of the company's stock, valued at approximately $5,718,616.95. This trade represents a 17.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 111,816 shares of company stock valued at $3,603,914. Insiders own 2.71% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. raised its holdings in shares of Ionis Pharmaceuticals by 9.4% during the fourth quarter. Vanguard Group Inc. now owns 16,472,539 shares of the company's stock worth $575,880,000 after acquiring an additional 1,416,781 shares during the period. Capital World Investors increased its holdings in Ionis Pharmaceuticals by 46.5% during the 4th quarter. Capital World Investors now owns 11,465,413 shares of the company's stock worth $400,831,000 after purchasing an additional 3,637,041 shares in the last quarter. Orbimed Advisors LLC raised its stake in shares of Ionis Pharmaceuticals by 21.2% in the 4th quarter. Orbimed Advisors LLC now owns 2,817,347 shares of the company's stock valued at $98,494,000 after purchasing an additional 492,900 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Ionis Pharmaceuticals by 0.7% in the fourth quarter. Geode Capital Management LLC now owns 2,687,248 shares of the company's stock valued at $93,976,000 after purchasing an additional 18,890 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of Ionis Pharmaceuticals in the fourth quarter valued at approximately $59,948,000. Institutional investors own 93.86% of the company's stock.

Ionis Pharmaceuticals Stock Up 5.9 %

Shares of Ionis Pharmaceuticals stock traded up $1.84 during trading hours on Thursday, hitting $33.19. 2,008,896 shares of the company's stock traded hands, compared to its average volume of 1,670,240. Ionis Pharmaceuticals has a twelve month low of $30.23 and a twelve month high of $52.34. The company has a market cap of $5.28 billion, a PE ratio of -10.92 and a beta of 0.34. The company has a quick ratio of 8.82, a current ratio of 8.47 and a debt-to-equity ratio of 2.12. The stock has a 50 day simple moving average of $33.18 and a 200-day simple moving average of $37.78.

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last announced its quarterly earnings data on Wednesday, February 19th. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($1.12) by $0.46. The company had revenue of $227.00 million during the quarter, compared to analyst estimates of $140.97 million. Ionis Pharmaceuticals had a negative net margin of 64.25% and a negative return on equity of 100.05%. The firm's revenue for the quarter was down 30.2% compared to the same quarter last year. During the same period last year, the business earned $0.12 EPS. Equities research analysts anticipate that Ionis Pharmaceuticals will post -3.5 earnings per share for the current fiscal year.

About Ionis Pharmaceuticals

(Get Free Report

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.

See Also

Analyst Recommendations for Ionis Pharmaceuticals (NASDAQ:IONS)

Should You Invest $1,000 in Ionis Pharmaceuticals Right Now?

Before you consider Ionis Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ionis Pharmaceuticals wasn't on the list.

While Ionis Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

Institutions Are Dumping These 3 Stocks—Should You?
Will Tesla’s Robot Future Save Its Falling Stock?
NVIDIA’s Dip Is a Gift—Here’s Why It Won’t Last

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads